{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:33:16Z","timestamp":1792978396022,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Technion - Israel Institute of Technology","id":[{"id":"https:\/\/ror.org\/03qryx823","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Women with\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      pathogenic variants face increased risks of breast and ovarian cancers. Our study aimed to evaluate the impact of hormonal contraceptive use on these risks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This matched cohort study included 1677 women who were found to carry a\n                      <jats:italic>BRCA1<\/jats:italic>\n                      \/\n                      <jats:italic>2<\/jats:italic>\n                      pathogenic variant. A Cox proportional hazards model was used to estimate hazard ratios associated with oral contraceptive use and with levonorgestrel-releasing intrauterine device use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among\n                      <jats:italic>BRCA1<\/jats:italic>\n                      carriers (n\u2009=\u2009990), oral contraceptive use was not associated with breast cancer risk (HR\u2009=\u20090.90, 95% CI 0.77\u20131.05, p\u2009=\u20090.2). Among\n                      <jats:italic>BRCA2<\/jats:italic>\n                      carriers (n\u2009=\u2009687), oral contraceptive use was associated with reduced breast cancer risk (HR\u2009=\u20090.80, 95% CI 0.65\u20130.99, p\u2009=\u20090.04), although duration-stratified analyses did not demonstrate a consistent dose\u2013response relationship. Oral contraceptive use was associated with a decrease in the risk of ovarian cancer in\n                      <jats:italic>BRCA2<\/jats:italic>\n                      carriers (HR\u2009=\u20090.57, 95% CI 0.35\u20130.94, p\u2009=\u20090.028), with the strongest protective effect observed among\n                      <jats:italic>BRCA2<\/jats:italic>\n                      carriers who used an oral contraceptive for more than 5\u00a0years (HR\u2009=\u20090.13; 95% CI 0.02\u20130.92). The protective effect of oral contraceptive use was less profound for\n                      <jats:italic>BRCA1<\/jats:italic>\n                      carriers. The use of a levonorgestrel-releasing intrauterine device was not associated with breast or ovarian cancer risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The use of an oral contraceptive was associated with reduced risks of breast and ovarian cancer among BRCA2 carriers, although the observed association with breast cancer should be interpreted cautiously given the absence of a consistent duration-response pattern. There was no increase in the risk of breast cancer among\n                      <jats:italic>BRCA1<\/jats:italic>\n                      carriers who used an oral contraceptive. No association with either cancer was found among users of a levonorgestrel-releasing intrauterine device.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12282-026-01890-z","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:52:13Z","timestamp":1787028733000},"page":"1271-1279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hormonal contraceptives and cancer risk in women with a BRCA1 or BRCA2 pathogenic variant"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0786-6934","authenticated-orcid":false,"given":"Chen","family":"Nahshon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Fahoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Hadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Michaelson-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Regev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meirav","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisam","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakir","family":"Segev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"1890_CR1","unstructured":"Isaacs C, Peshkin BN. Cancer risks and management of BRCA1\/2 carriers without cancer. In: UpToDate. 2020. https:\/\/www.uptodate.com\/contents\/cancer-risks-and-management-of-brca1-2-carriers-without-cancer?csi=ff80adfe-d416-4fa3-87a0-26a00820ea8a&source=contentShare"},{"issue":"23","key":"1890_CR2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316. https:\/\/doi.org\/10.1001\/jama.2017.7112.","journal-title":"JAMA"},{"issue":"3","key":"1890_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/CGE.14098","volume":"101","author":"A Finch","year":"2022","unstructured":"Finch A, Metcalfe K, Akbari M, et al. The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele BRCA2 6174delT. Clin Genet. 2022;101(3):317\u201323. https:\/\/doi.org\/10.1111\/CGE.14098.","journal-title":"Clin Genet"},{"key":"1890_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/J.GIMO.2023.100824","author":"R Greenberg","year":"2023","unstructured":"Greenberg R, Aharonov-Majar E, Isakov O, et al. Carrier screening program for BRCA1\/BRCA2 pathogenic variants among Ashkenazi Jewish women in Israel: an observational study. Genet Med Open. 2023. https:\/\/doi.org\/10.1016\/J.GIMO.2023.100824.","journal-title":"Genet Med Open"},{"issue":"4","key":"1890_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.6004\/JNCCN.2020.0017","volume":"18","author":"MB Daly","year":"2020","unstructured":"Daly MB, Pilarski R, Yurgelun MB, et al. NCCN guidelines insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020: featured updates to the NCCN guidelines. J Nat Compr Cancer Netw. 2020;18(4):380\u201391. https:\/\/doi.org\/10.6004\/JNCCN.2020.0017.","journal-title":"J Nat Compr Cancer Netw"},{"issue":"1","key":"1890_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/AOG.0B013E3182783C2F","volume":"121","author":"JS Kwon","year":"2013","unstructured":"Kwon JS, Tinker A, Pansegrau G, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol. 2013;121(1):14\u201324. https:\/\/doi.org\/10.1097\/AOG.0B013E3182783C2F.","journal-title":"Obstet Gynecol"},{"issue":"33","key":"1890_CR7","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","volume":"31","author":"PG Moorman","year":"2013","unstructured":"Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188\u201398. https:\/\/doi.org\/10.1200\/JCO.2013.48.9021.","journal-title":"J Clin Oncol"},{"issue":"9609","key":"1890_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","volume":"371","author":"V Beral","year":"2008","unstructured":"Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet. 2008;371(9609):303\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(08)60167-1.","journal-title":"Lancet"},{"issue":"2","key":"1890_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/HUMUPD\/DMAC038","volume":"29","author":"MHD Van Bommel","year":"2023","unstructured":"Van Bommel MHD, Inthout J, Veldmate G, et al. Contraceptives and cancer risks in BRCA1\/2 pathogenic variant carriers: a systematic review and meta-analysis. Hum Reprod Update. 2023;29(2):197\u2013217. https:\/\/doi.org\/10.1093\/HUMUPD\/DMAC038.","journal-title":"Hum Reprod Update"},{"issue":"1","key":"1890_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/AOG.0B013E318291C235","volume":"122","author":"LJ Havrilesky","year":"2013","unstructured":"Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013;122(1):139\u201347. https:\/\/doi.org\/10.1097\/AOG.0B013E318291C235.","journal-title":"Obstet Gynecol"},{"issue":"7","key":"1890_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJM199808133390702","volume":"339","author":"SA Narod","year":"1998","unstructured":"Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 1998;339(7):424\u20138. https:\/\/doi.org\/10.1056\/NEJM199808133390702.","journal-title":"N Engl J Med"},{"issue":"2","key":"1890_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/J.AJOG.2023.03.039","volume":"229","author":"N Minalt","year":"2023","unstructured":"Minalt N, Caldwell A, Yedlicka GM, et al. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. Am J Obstet Gynecol. 2023;229(2):93\u2013100. https:\/\/doi.org\/10.1016\/J.AJOG.2023.03.039.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"1890_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1089\/JWH.2015.5191","volume":"24","author":"NE Birgisson","year":"2015","unstructured":"Birgisson NE, Zhao Q, Secura GM, Madden T, Peipert JF. Preventing unintended pregnancy: the contraceptive CHOICE project in review. J Womens Health. 2015;24(5):349\u201353. https:\/\/doi.org\/10.1089\/JWH.2015.5191.","journal-title":"J Womens Health"},{"key":"1890_CR14","volume-title":"Speroff & Darney\u2019s clinical guide to contraception","author":"JT Jensen","year":"2020","unstructured":"Jensen JT, Creinin MD. Speroff & Darney\u2019s clinical guide to contraception. 6th ed. Lippincott Williams & Wilkins, a Wolters Kluwer Business; 2020.","edition":"6"},{"issue":"4","key":"1890_CR15","doi-asserted-by":"publisher","first-page":"450.e1","DOI":"10.1016\/j.ajog.2024.05.011","volume":"231","author":"H Yi","year":"2024","unstructured":"Yi H, Zhang N, Huang J, et al. Association of levonorgestrel-releasing intrauterine device with gynecologic and breast cancers: a national cohort study in Sweden. Am J Obstet Gynecol. 2024;231(4):450.e1-450.e12. https:\/\/doi.org\/10.1016\/j.ajog.2024.05.011.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1890_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/IJGO.13737","volume":"156","author":"G D\u2019Alessandro","year":"2022","unstructured":"D\u2019Alessandro G, Frigerio M, Barra F, Costantini S, Gustavino C, Ferrero S. Systematic review and meta-analysis on the impact of the levonorgestrel-releasing intrauterine system in reducing risk of ovarian cancer. Int J Gynaecol Obstet. 2022;156(3):418\u201324. https:\/\/doi.org\/10.1002\/IJGO.13737.","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"1890_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/IJC.33531","volume":"149","author":"J Yang","year":"2021","unstructured":"Yang J, Sasamoto N, Babic A, et al. Intrauterine device use and risk of ovarian cancer: results from the New England Case-control study and nurses\u2019 health studies. Int J Cancer. 2021;149(1):75\u201383. https:\/\/doi.org\/10.1002\/IJC.33531.","journal-title":"Int J Cancer"},{"issue":"11","key":"1890_CR18","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/0284186X.2016.1175660","volume":"55","author":"T Soini","year":"2016","unstructured":"Soini T, Hurskainen R, Gr\u00e9nman S, M\u00e4enp\u00e4\u00e4 J, Paavonen J, Pukkala E. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube. Acta Oncol (Madr). 2016;55(11):1281\u20134. https:\/\/doi.org\/10.1080\/0284186X.2016.1175660.","journal-title":"Acta Oncol (Madr)"},{"issue":"1","key":"1890_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2018.02.006","volume":"149","author":"M Jareid","year":"2018","unstructured":"Jareid M, Thalabard JC, Aarflot M, B\u00f8velstad HM, Lund E, Braaten T. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol. 2018;149(1):127\u201332. https:\/\/doi.org\/10.1016\/j.ygyno.2018.02.006.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1890_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/J.YGYNO.2022.01.014","volume":"164","author":"YY Xia","year":"2022","unstructured":"Xia YY, Gronwald J, Karlan B, et al. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2022;164(3):514\u201321. https:\/\/doi.org\/10.1016\/J.YGYNO.2022.01.014.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1890_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1200\/JCO.24.00176","volume":"43","author":"KA Phillips","year":"2025","unstructured":"Phillips KA, Kotsopoulos J, Domchek SM, et al. Hormonal contraception and breast cancer risk for carriers of germline mutations in BRCA1 and BRCA2. J Clin Oncol. 2025;43(4):422\u201331. https:\/\/doi.org\/10.1200\/JCO.24.00176.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1890_CR22","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1056\/NEJMOA2201688","volume":"386","author":"O Magen","year":"2022","unstructured":"Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2022;386(17):1603\u201314. https:\/\/doi.org\/10.1056\/NEJMOA2201688.","journal-title":"N Engl J Med"},{"issue":"12","key":"1890_CR23","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/J.EJCA.2010.04.018","volume":"46","author":"S Iodice","year":"2010","unstructured":"Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis. Eur J Cancer. 2010;46(12):2275\u201384. https:\/\/doi.org\/10.1016\/J.EJCA.2010.04.018.","journal-title":"Eur J Cancer"},{"key":"1890_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJU091","author":"TM Friebel","year":"2014","unstructured":"Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst. 2014. https:\/\/doi.org\/10.1093\/JNCI\/DJU091.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1890_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S1470-2045(06)70983-4","volume":"8","author":"JR McLaughlin","year":"2007","unstructured":"McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007;8(1):26\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(06)70983-4.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1890_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/IJC.10696","volume":"102","author":"C Bosetti","year":"2002","unstructured":"Bosetti C, Negri E, Trichopoulos D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer. 2002;102(3):262\u20135. https:\/\/doi.org\/10.1002\/IJC.10696.","journal-title":"Int J Cancer"},{"issue":"1","key":"1890_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/IJC.2910490112","volume":"49","author":"S Franceschi","year":"1991","unstructured":"Franceschi S, Parazzini F, Negri E, et al. Pooled analysis of 3 European case\u2010control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer. 1991;49(1):61\u20135. https:\/\/doi.org\/10.1002\/IJC.2910490112.","journal-title":"Int J Cancer"},{"issue":"6","key":"1890_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/J.BPOBGYN.2014.06.003","volume":"28","author":"MV Dragoman","year":"2014","unstructured":"Dragoman MV. The combined oral contraceptive pill- recent developments, risks and benefits. Best Pract Res Clin Obstet Gynaecol. 2014;28(6):825\u201334. https:\/\/doi.org\/10.1016\/J.BPOBGYN.2014.06.003.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"1890_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/S10815-019-01624-5","volume":"37","author":"E Dinehart","year":"2020","unstructured":"Dinehart E, Lathi RB, Aghajanova L. Levonorgestrel IUD: is there a long-lasting effect on return to fertility? J Assist Reprod Genet. 2020;37(1):45\u201352. https:\/\/doi.org\/10.1007\/S10815-019-01624-5.","journal-title":"J Assist Reprod Genet"},{"issue":"7716","key":"1890_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","volume":"298","author":"MF Fathalla","year":"1971","unstructured":"Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia\u202f? Lancet. 1971;298(7716):163. https:\/\/doi.org\/10.1016\/S0140-6736(71)92335-X.","journal-title":"Lancet"},{"issue":"3","key":"1890_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/S10549-013-2823-4","volume":"143","author":"J Kotsopoulos","year":"2014","unstructured":"Kotsopoulos J, Lubinski J, Moller P, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat. 2014;143(3):579\u201386. https:\/\/doi.org\/10.1007\/S10549-013-2823-4.","journal-title":"Breast Cancer Res Treat"},{"key":"1890_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/JNCICS\/PKY023","author":"LH Schrijver","year":"2018","unstructured":"Schrijver LH, Olsson H, Phillips KA, et al. Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study. JNCI Cancer Spectr. 2018. https:\/\/doi.org\/10.1093\/JNCICS\/PKY023.","journal-title":"JNCI Cancer Spectr"},{"key":"1890_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS25115894","author":"D Huber","year":"2024","unstructured":"Huber D, Hatzipanagiotou M, Sch\u00fcler-Toprak S, Ortmann O, Treeck O. Effects of endocrine interventions targeting ER\u03b1 or PR on breast cancer risk in the general population and carriers of BRCA1\/2 pathogenic variants. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/IJMS25115894.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1890_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/GCC.10321","volume":"39","author":"PA Mote","year":"2004","unstructured":"Mote PA, Leary JA, Avery KA, et al. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer. 2004;39(3):236\u201348. https:\/\/doi.org\/10.1002\/GCC.10321.","journal-title":"Genes Chromosomes Cancer"},{"key":"1890_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/J.CANLET.2021.07.034","volume":"520","author":"O Lee","year":"2021","unstructured":"Lee O, Bosland MC, Wang M, et al. Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes. Cancer Lett. 2021;520:255\u201366. https:\/\/doi.org\/10.1016\/J.CANLET.2021.07.034.","journal-title":"Cancer Lett"},{"issue":"8","key":"1890_CR36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/AOGS.13817","volume":"99","author":"L Conz","year":"2020","unstructured":"Conz L, Mota BS, Bahamondes L, et al. Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2020;99(8):970\u201382. https:\/\/doi.org\/10.1111\/AOGS.13817.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1890_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2025.110867","volume":"147","author":"P Batur","year":"2025","unstructured":"Batur P, Brant A, McCourt C, Schwarz EB. Society of Family Planning Clinical Recommendation: contraceptive considerations for individuals with cancer and cancer survivors part 2 \u2013 breast, ovarian, uterine, and cervical cancer: joint with the society of gynecologic oncology. Contraception. 2025;147:110867. https:\/\/doi.org\/10.1016\/j.contraception.2025.110867.","journal-title":"Contraception"},{"issue":"2","key":"1890_CR38","doi-asserted-by":"publisher","first-page":"E128","DOI":"10.1097\/AOG.0000000000003072","volume":"133","author":"RH Allen","year":"2019","unstructured":"Allen RH, Kaunitz A, Bartz D. ACOG practice bulletin number 206: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019;133(2):E128\u201350. https:\/\/doi.org\/10.1097\/AOG.0000000000003072.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"1890_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/J.AJOG.2023.03.039","volume":"229","author":"N Minalt","year":"2023","unstructured":"Minalt N, Caldwell A, Yedlicka GM, et al. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. Am J Obstet Gynecol. 2023;229(2):93\u2013100. https:\/\/doi.org\/10.1016\/J.AJOG.2023.03.039.","journal-title":"Am J Obstet Gynecol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01890-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01890-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01890-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:02:24Z","timestamp":1792976544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01890-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1890"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01890-z","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}